Professor of Medicine
Nancy University Hospital
Laurent Peyrin-Biroulet, MD, PhD, is Full Professor of Medicine and Head of the Inflammatory Bowel Disease (IBD) Unit (Inserm U954) at Nancy University Hospital in Vandoeuvre-lès-Nancy, France. On receiving his MD and PhD, Prof Peyrin-Biroulet undertook a postdoctoral fellowship at the IBD Centre in Lille, France in 2007, before taking a research position at the Mayo Clinic in Rochester, Minnesota, USA, from 2008 to 2009.
Prof Peyrin-Biroulet received a Rising Star award in 2008 from the United European Gastroenterology Federation and was a member of the federation’s Scientific Committee from 2011 to 2014. He is Vice President of Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives and President of the Scientific Committee of the Association Francois Aupetit. Prof Peyrin-Biroulet is Chair of both the IBD Committee of Société Française d’Endoscopie Digestive and the Clinical Trials Task Force of the International Organization for the Study of IBD, and is General Secretary of the European Crohn´s and Colitis Organisation (ECCO). He also contributed to the ECCO workshops on mucosal healing and malignancies, and participated in development of the ECCO guidelines on imaging and CD consensus. Prof Peyrin-Biroulet was Coordinator for the development of the first IBD Disability Index, and proposed the first definitions of early CD and disease severity for IBD.
Prof Peyrin-Biroulet is the author of more than 300 peer-reviewed and more than 200 non-peer-reviewed articles over the past 10 years. He is an Associate Editor of Digestive and Liver Disease, and a member of the editorial boards of Alimentary Pharmacology & Therapeutics, Journal of Crohn’s and Colitis, and Gut. Prof Peyrin-Biroulet also serves as a reviewer for several international journals and is a staff contributor of the Selected Summaries section of Gastroenterology. He joined the editorial team of the Cochrane IBD and Functional Bowel Disorders Review Group in 2014, and serves as Councillor to the Immunology, Microbiology & IBD Section of the American Gastroenterological Association Institute Council.
Consultant Gastroenterologist, Barts Health NHS Trust
RReader in IBD at Barts and the London School of Medicine and Dentistry
Queen Mary University of London, United Kingdom
James O. Lindsay, PhD, BM BCh, FRCP, is a Consultant Gastroenterologist at Barts Health NHS Trust in London, United Kingdom. Along with a full multidisciplinary team, Dr Lindsay runs the adult and adolescent IBD services at The Royal London Hospital. He is Chair of the ECCO Education Committee and has led working groups for ECCO’s consensus on the management of CD and ulcerative colitis.
Dr Lindsay is a Reader in IBD at Barts and the London School of Medicine, Queen Mary University of London. He is the chief investigator for a series of investigator-led and commercial clinical trials in IBD, and serves on the British Society of Gastroenterology IBD Clinical Trials Steering Group. In addition, Dr Lindsay leads a translational research program in mucosal immunology.
Head, Inflammatory Bowel Disease Center
The Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Iris Dotan, MD, is Head of the Inflammatory Bowel Disease Center at The Tel Aviv Sourasky Medical Center in Tel Aviv, Israel, a tertiary referral center for IBD patients. Prof Dr Dotan received her MD from the Sackler Faculty of Medicine, Tel Aviv University in Tel Aviv. Her postdoctoral fellowship was completed at the Immunobiology Center at Mount Sinai Medical Center in New York, New York, USA, and focused on intestinal epithelial cell biology. Prof Dr Dotan is a specialist in internal medicine, gastroenterology, and liver diseases.
The overarching theme at the Inflammatory Bowel Disease Center is to provide cutting-edge care for patients and families. Prof Dr Dotan’s clinical and research interests focus on patient stratification as a basis for improved patient care, prevention of complications, and future cure of IBD. She has expertise in the use of biologics and novel therapies for IBD, and the follow-up of patients with ulcerative colitis before and after restorative proctocolectomy pouch surgery in a comprehensive, multidisciplinary pouch clinic. In addition, Prof Dr Dotan conducts translational research in mucosal immunology focusing on the interactions of mucosal lymphocytes with their environment, specifically epithelial cell-derived mediators and chemokines. She first described the new antiglycan antibodies and their relevance to CD a decade ago and is investigating the role of glycans in intestinal immune responses.